Aer Therapeutics is a clinical stage biopharmaceutical company developing a novel inhaled approach to treat lung disease with excess mucus and mucus plugs. We are focused on treating respiratory diseases with significant unmet need, such as COPD, cystic fibrosis and asthma.
Our technology was developed and spun out of Dr. John Fahy’s airway biology lab at University of California San Francisco (UCSF) in collaboration with Dr. Stefan Oscarson’s glycochemistry lab at University College Dublin and Dr. Anne Marie Healy’s pharmaceutics lab at Trinity College Dublin. The efforts of this research consortium led to over $18M in NIH grant funding, resulting in the identification of our lead therapeutic candidate (AER-01), establishment of preliminary safety and efficacy profiles, and the production of clinical trial API.
Company Details
- Employees
- 10
- Founded
- -
- Address
- San Francisco, Ca, Us
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://aertherapeutics.com
- HQ
- San Francisco, CA
Aer Therapeutics, Inc. Questions
Aer Therapeutics, Inc.'s website is http://aertherapeutics.com
Aer Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/aer-therapeutics-inc.
Aer Therapeutics, Inc. has
10 employees.
View email and phone details for 10
employees at Aer Therapeutics, Inc..
Aer Therapeutics, Inc.'s industry is
Pharmaceutical Manufacturing
Aer Therapeutics, Inc.'s top competitors are
Allievex Corporation,
Avalyn Pharma,
Ten63 Therapeutics,
Apogee Therapeutics,
Blueprint Biosolutions,
Istari Oncology,
Trefoil Therapeutics,
Altis Biosystems,
Locus Biosciences, Inc.,
Plakous Therapeutics.
Aer Therapeutics, Inc.'s categories are Pharmaceutical Manufacturing
Aer Therapeutics, Inc.'s founding year is 2014
